You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    Project Summary The goal of this Fast Track STTR project is to determine proof-of-principle and efficacy of a novel blood brain barrier (BBB) penetrating therapeutic nanoparticle for the potential treatment of otherwise intractable brain tumors like glioblastoma multiforme (GBM). This project seeks to demonstrate that novel, targetable nanoparticles can delivery therapeutic substances to human bra ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.

    SBC: Opio Connect, Inc.            Topic: NIDA

    The goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options

    SBC: Golden Helix, Inc.            Topic: 172

    Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Spray Dried Powder Compositions for Dual-use Secondary High Explosive and Rocket Propellants

    SBC: DIVISION BY ZERO DEVELOPMENT LABS LLC            Topic: A21CT001

    The U.S. Army has a future need for multiple secondary high explosive compositions that can also be used interchangeably as rocket propellants. In this proposal we will discuss a method of preparing such compositions via advanced spray drying technology and involving the use of a highly insensitive spray dried nitramine or CL-20 composition which have been plasticized with an energetic polymer t ...

    STTR Phase I 2022 Department of DefenseArmy
  6. Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery

    SBC: MONTANA MOLECULAR LLC            Topic: NIAID

    SUMMARY STATEMENT The SARS-CoV-2 virus depends upon two proteases for replication, 3CLpro and PLpro. If one or both of these proteases can be blocked, COVID-19 infection can be effectively treated. Montana Molecular makes and sells live cell, fluorescent biosensor assays for disease research and drug discovery. In response to the COVID-19 pandemic, Montana Molecular applied its expertise and backg ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.

    SBC: Opio Connect, Inc.            Topic: NIDA

    The goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Resonant Acoustic Continuous Crystallizer for Safe and Tunable Recrystallization of Nitramines

    SBC: RESODYN CORPORATION            Topic: A20101

    Resodyn has developed the novel Resonant Acoustic Continuous Crystallizer (RACC) concept which is specifically configured for the recrystallization of energetic nitramines. This technology employs the Resonant Acoustic Mixing technology, which results in a uniform shear field throughout the mixing vessel. Radial mixing is accomplished to such a significant degree that true plug flow is achieved. C ...

    SBIR Phase I 2021 Department of DefenseArmy
  9. Novel therapeutic target to combat cutaneous lupus

    SBC: DERMAXON LLC            Topic: NCATS

    Project Summary / Abstract: Chronic auto-inflammatory skin diseases such as cutaneous lupus erythematosus (CLE) affect millions of Americans with limited therapeutic options currently available, creating a significant need for novel therapeutic options. A hallmark of CLE is the presence of autoantibodies against nucleic acids and nucleic acid-binding proteins, as well as elevated interferons (IFNs ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation

    SBC: RESTOREAR DEVICES LLC            Topic: NIDCD

    Project Summary The goal of our project is to finalize, validate, and prepare for regulatory approvals a device and probe for delivering localized, controlled therapeutic hypothermia to the inner ear. The device safety and efficacy will be tested for residual hearing preservation in cochlear implant surgeries by comparing pre- and post-operative hearing outcomes and intra-operative electrophysiolo ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government